Table 4 Prognostic factors of overall survival: univariate and multivariate analysis
From: From IB2 to IIIB locally advanced cervical cancers: report of a ten-year experience
Variables | Tested vs adverse criteria | Adverse criterion present median overall survival (months) | Adverse criterion absent median overall survival (months) | p-value (Log rank test) | Adjusted Hazard Ratio | 95% CI | p-value (Cox model) |
|---|---|---|---|---|---|---|---|
Age (years) | ≥ 65 (vs < 65) | 73.1 | 90.9 | p = 0.361 | – | – | – |
PS | PS > 1 (vs ≤ 1) | 48.6 | > 124.0* | p < 0.001 | 2.86 | 1.41–5.79 | p = 0.003 |
Histology | No SCC (vs SCC) | 61.2 | 124.9 | p = 0.262 | – | – | – |
Differentiation | Moderate or low (vs high) | 73.1 | 90.9 | p = 0.899 | – | – | – |
FIGO stage | III (vs IB2 and II) | 37.4 | 90.9 | p = 0.336 | – | – | – |
Pelvic lymph nodes involvement | Yes (vs no) | 41.1 | > 73.1* | p = 0.003 | 1.95 | 1.03–3.69 | p = 0.040 |
MRI tumor size (mm) | ≥ 50 (vs < 50) | 32 | > 124.9* | p = 0.006 | – | – | – |
Hemoglobin (g/dL) | < 11 (vs ≥ 11) | 13.0 | > 63.0* | p = 0.013 | – | – | – |
Radiotherapy | 3D–CRT (vs IMRT or VMAT) | 73 | > 61.0* | p = 0.500 | |||
Concurrent chemotherapy | No (vs yes) | 17 | 125.0 | p = 0.014 | 2.33 | 1.06–5.16 | p = 0.035 |
Brachytherapy | No (vs yes) | 37.4 | 124.9 | p = 0.428 | – | – | – |
OTT (days) | > 55 (vs ≤ 55) | 62.9 | 124.9 | p = 0.428 | – | – | – |
Complete tumor sterilization | No (vs yes) | 90.9 | > 69.1* | p = 0.256 | – | – | – |